Valeant: Improved offer for Allergan will not be all in cash

|About: Valeant Pharmaceuticals I... (VRX)|By:, SA News Editor

Valeant (VRX) says that any improved bid for Allergan (AGN) "will not be an all cash deal."

Valeant intends to sweeten its $45.7B cash-and-stock offer based on feedback that the Canadian company hopes to receive during a meeting with stockholders from both companies on May 28.

At the meeting, Valeant also plans to respond to Allergan assertions that Valeant's model is not sustainable, that Bausch & Lomb is not growing, that the company slashes R&D and is not committed to innovation, and that it will be impossible to generate $2.7B of synergies without affecting sales growth. (PR)

Previous coverage